<DOC>
	<DOC>NCT00580125</DOC>
	<brief_summary>The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.</brief_summary>
	<brief_title>Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Key inclusion criteria include: Have a current diagnosis of schizophrenia. Increase in symptoms over the past 24 weeks. Willing to remain inpatients for the duration of the trial. Subjects with a current DSMIV axis I diagnosis other than schizophrenia Subjects who meet the DSMIV criteria for psychoactive substance abuse and dependence Subjects with a history of treatment resistant schizophrenia Females of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>